Table 3

 Testing all women with point-of-care (POC) tests compared with syndromic approach (SA)—according to treatment regimen, universal- or age-based management and test sensitivity: expected and incremental costs and effects per 1000 attendees included in the programme, and total programme costs and effects in a population of 100 000 antenatal care attendees*

StrategyCost (US$)Incremental cost (US$)Effectiveness (cured cases)Incremental effectiveness (cured cases)Cost per cured case (US$)Incremental cost per cured case (US$)Total programme costs (US$)Total programme effectiveness (cured cases)
Total
*Assuming that 19.5% of the attendees are less than 20 years of age and 74.0% are less than 30, and a C trachomatis prevalence of 15.8% among attendees less than 20 years of age and 9.3% among attendees less than 30 and 7.5% in the general population
Erythromycin
    Including allSA5447286654 400800
POC 0.50110456015622135142110 4002200
POC 0.65112457920828204029112 4002800
POC 0.75113759223932243525113 7003200
POC 0.851150605261036283222115 0003600
    Including <30SA54882105440 600700
POC 0.5011195711982717423582 8002000
POC 0.65114359525103524332484 6002600
POC 0.75115961129114030292185 8003000
POC 0.85117662732134535261887 0003300
    Including <20SA562144173211 000300
POC 0.50117461232134528262222 900900
POC 0.65121565342175941211623 7001200
POC 0.75124268049196850181424 2001300
POC 0.85126970755227759171224 7001500
Azithromycin
    Including allSA314123152131 4001500
POC 0.5010687541772494587106 8002400
POC 0.65108076622931163549108 0003100
POC 0.751088773251035203138108 8003500
POC 0.851095781291140252731109 5004000
    Including <30SA316153191723 4001400
POC 0.5010777612182911377179 7002100
POC 0.65109277527113819294080 8002800
POC 0.75110178532124425253181 5003300
POC 0.85111179436144931222682 2003600
Including <20SA32426532106300600
POC 0.50111078536145018224321 6001000
POC 0.65113081046186533182522 0001300
POC 0.75115083054217543151922 4001500
POC 0.85117084061238453141622 8001600